Asterias cautiously optimistic on 9-month study of stem cell trials

Asterias Biotherpeutics, the company behind the current embryonic stem cell clinical trials, announced last week the results of its study involving six spinal cord injured individuals following nine months from the initial stem cell injection.

While the results involve a very small sample, the results are providing enthusiasm for what can happen as the company ramps up the amount of stem cells it injects into its future subjects taking part in these clinical trials.  

You can read more about the results HERE.